Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Fluzoparib |
Synonyms | |
Therapy Description |
Fluzoparib (SHR3162) is a PARP inhibitor, which potentially induces DNA damage, cell cycle arrest and apoptosis, and inhibits cell proliferation and tumor growth (PMID: 30663191, PMID: 32694901). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fluzoparib | HS10160|SHR-3162|SHR3162|Fuzuloparib | PARP Inhibitor (Pan) 30 | Fluzoparib (SHR3162) is a PARP inhibitor, which potentially induces DNA damage, cell cycle arrest and apoptosis, and inhibits cell proliferation and tumor growth (PMID: 30663191, PMID: 32694901). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BARD1 D135N | breast cancer | predicted - sensitive | Fluzoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Fluzoparib (SHR3162) treatment inhibited proliferation of a BARD1-deficient breast cancer cell line expressing BARD1 D135N in culture (PMID: 33933153). | 33933153 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|